Inhibitors of LRRK2 such as DNL201 and DNL151 have been studied in large randomized, double-blinded placebo-controlled Phase 1b studies in PD (NCT03710707, NCT04056689) and have shown promise in modifying lysosomal dysfunction in PD [230]. Here, LRRK2 is linked to Parkinson disease.